This information is intended for use by health professionals
Traxam Pain Relief 3% w/w Gel
Each gram of gel contains 30 mg of Felbinac
For a full list of excipients, see section 6.1
A clear non-greasy, non-staining gel.
Traxam Pain Relief Gel is a topical anti-inflammatory and analgesic. It is indicated for the relief of rheumatic pain, pain of non-serious arthritic conditions and soft tissue injuries such as sprains, strains and contusions.
Rub 1g Traxam Gel (approximately 1 inch (2.5cm) of gel) into the affected area(s) 2 to 4 times a day. Do not use for longer than 7 days.
The total daily dose should not exceed 25g per day regardless of the number of affected areas.
Elderly: No special dosage recommendations are made for elderly patients.
Children: Not recommended for use in children under 12 years of age.
Hands should be washed following application of Traxam Gel unless they are the treatment site.
Hypersensitivity to the ingredients. Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory drugs. Children under 12 years of age.
Use of Traxam Gel should be limited to intact and non-diseased skin. Contact with mucous membranes and the eyes should be avoided.
Discontinue if rash develops.
Felbinac gel should not be applied with occlusive dressings at the same site as other topical preparations.
Topical application of large amounts may result in systemic effects, such as hypersensitivity, asthma and renal disease.
To avoid the possibility of photosensitivity, patients are advised against excessive exposure to sunlight of treated areas.
Safe use of Felbinac in early childhood has not been established.
Felbinac is highly protein bound. However, serum levels following topical application are extremely low and therefore clinical drug interactions are unlikely.
Concurrent use of aspirin or other NSAIDs may result in an increased incidence of adverse reactions.
Since the safety of felbinac in human pregnancy and lactation has not been established, its use in these circumstances is not recommended. As with other non-steroidal anti-inflammatory agents which inhibit prostaglandin synthesis, dystocia and delayed parturition were observed when felbinac was administered simultaneously in animal studies.
The overall incidence of side effects reported with Traxam Gel is low (less than 2%). Local effects such as mild erythema, irritation, dermatitis, pruritis and paraesthesia, which recover spontaneously upon cessation of treatment are the most common reactions.
Anaphylaxis; respiratory reactivity comprising asthma, aggravated asthma or dyspnoea; purpura; angioedema; bullous dermatoses (including epidermal necrolysis and erythema multiforme) and skin photosensitivity have been reported.
Systemic side effects are rare; gastrointestinal disturbances and hypersensitivity reactions such as widespread rashes (including urticaria) and bronchospasm have been reported with felbinac.
Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
If accidentally ingested, treatment should be symptomatic and supportive. Correction of severe electrolyte abnormalities should be considered.
Felbinac is an anti-inflammatory/analgesic agent which has been developed into a topical gel for local treatment and pain and inflammation associated with conditions of the musculo-skeletal system.
Clinical pharmacokinetic studies show that a topical dose of 10g felbinac gel results in low circulating levels of felbinac in serum (600ng/ml). This is more than 20 times less than the levels recorded following oral administration of a single dose of 600mg fenbufen.
Results of distribution studies demonstrate that felbinac is transferred preferentially to a site of inflammation when applied topically.
The metabolism of felbinac is consistent with the known metabolic profile of fenbufen.
Testing of biphenyl acetic acid includes single and repeat dose studies, foetal toxicity and fertility studies, mutagenic and carcinogenic potential studies which show an acceptable toxicity profile for the active ingredient.
1. Fluorovinyl resin-coated blind ended Aluminium Tubes with a plastic cap:
2. LDPE/Aluminium Foil/LDPE laminate tubes with a plastic cap:
3. Polyamide-imide or epoxyphenolic coated blind ended aluminium tubes with a plastic cap:
Traxam Gel is packed in fluorovinyl resin-coated blind ended Aluminium Tubes with a plastic cap, LDPE/Aluminium Foil/LDPE laminate tubes with a plastic cap or Polyamide-imide or epoxyphenolic coated blind ended aluminium tubes with a plastic cap.
Pack sizes: 7.5g, 25g, 30g
Mercury Pharmaceuticals Ltd
No. 1 Croydon,
12-16 Addiscombe Road,
Croydon CR0 0XT, UK